FOXO3a inhibited ER-mediated signaling through a nongenomic mechanism and upregulated the expression of three CDK inhibitors that could result in suppression of tumor growth and tumorigenesis in estrogen-dependent breast cancer cells in vivo. This evidence concerns the gene FOXO3 and breast carcinoma.